Edition:
United States

Genfit SA (GNFT.PA)

GNFT.PA on Paris Stock Exchange

21.82EUR
15 Dec 2017
Change (% chg)

€0.06 (+0.28%)
Prev Close
€21.76
Open
€21.83
Day's High
€22.04
Day's Low
€21.73
Volume
90,382
Avg. Vol
150,945
52-wk High
€35.65
52-wk Low
€20.11

Chart for

About

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect... (more)

Overall

Beta: 1.60
Market Cap(Mil.): €680.05
Shares Outstanding(Mil.): 31.17
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Genfit announces positive outcome of DSMB safety review

* REG-GENFIT: POSITIVE OUTCOME FROM THE 18-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR

Nov 22 2017

BRIEF-Genfit completes offering of convertible bonds due 2022 for 180 million euros

* REG-GENFIT COMPLETES A €180 MILLION OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022

Oct 17 2017

BRIEF-Genfit completes convertible bonds offering for amount of 180 million euros

* REG-GENFIT ANNOUNCES THE SUCCESS OF ITS OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF €180 MILLION

Oct 11 2017

BRIEF-Genfit reports‍ nine months revenues at 91 thousand euros

* ‍CASH AND CASH EQUIVALENTS OF EUR 113.8 MILLION AT SEPTEMBER 30, 2017​

Oct 11 2017

BRIEF-Genfit launches an offering of conbertible bonds for around 150 million euros

* GENFIT LAUNCHES AN OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF APPROXIMATELY €150 MILLION

Oct 11 2017

BRIEF-Genfit's combination of two pharmacopoeia​ drugs show anti-fibrotic potential

* ‍NEW RESULTS INDICATING A SUBSTANTIAL ANTI-FIBROTIC POTENTIAL OF A PROPRIETARY COMBINATION OF TWO DRUGS FROM PHARMACOPOEIA​

Oct 02 2017

BRIEF-Genfit H1 operating loss widens to 22.4 million euros

* REG-GENFIT: 2017 HALF-YEAR RESULTS: CASH POSITION AT END OF PERIOD AT €126M AND SIGNIFICANT ADVANCES IN THE COMPANY'S PIPELINE

Sep 25 2017

BRIEF-Genfit alerts public to potential risk of confusion between elafibranor and lanifibranor

* REG-GENFIT: RISK OF CONFUSION BETWEEN PPAR ALPHA/DELTA PHASE 3 DRUG CANDIDATE ELAFIBRANOR AND PPAR A/D/GAMMA PHASE 2 COMPOUND LANIFIBRANOR

Sep 20 2017

BRIEF-Genfit says hits milestone towards development of non-invasive IVD test for NASH

* REG-GENFIT REACHES A CRITICAL MILESTONE TOWARDS THE DEVELOPMENT OF A NON-INVASIVE IN VITRO DIAGNOSTIC (IVD) TEST FOR NASH

Jun 23 2017

Earnings vs. Estimates